Ionis Pharmaceuticals, Inc. (IONS)
NASDAQ: IONS · Real-Time Price · USD
34.89
-0.51 (-1.44%)
Nov 21, 2024, 11:43 AM EST - Market open
Ionis Pharmaceuticals Stock Forecast
Stock Price Forecast
The 16 analysts with 12-month price forecasts for IONS stock have an average target of 62, with a low estimate of 37 and a high estimate of 77. The average target predicts an increase of 77.70% from the current stock price of 34.89.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for IONS stock from 18 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jun '24 | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 5 | 5 | 5 | 5 | 5 |
| Buy | 5 | 6 | 6 | 6 | 6 | 7 |
| Hold | 4 | 4 | 6 | 6 | 6 | 5 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Total | 13 | 16 | 18 | 18 | 18 | 18 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Piper Sandler | Piper Sandler | Buy Maintains $65 → $62 | Buy | Maintains | $65 → $62 | +77.70% | Nov 14, 2024 |
| Wells Fargo | Wells Fargo | Buy Maintains $82 → $77 | Buy | Maintains | $82 → $77 | +120.69% | Nov 7, 2024 |
| Needham | Needham | Strong Buy Reiterates $60 | Strong Buy | Reiterates | $60 | +71.97% | Nov 7, 2024 |
| Guggenheim | Guggenheim | Strong Buy Maintains $70 → $65 | Strong Buy | Maintains | $70 → $65 | +86.30% | Oct 9, 2024 |
| RBC Capital | RBC Capital | Buy Reiterates $70 | Buy | Reiterates | $70 | +100.63% | Sep 26, 2024 |
Financial Forecast
Revenue This Year
637.93M
from 787.65M
Decreased by -19.01%
Revenue Next Year
741.99M
from 637.93M
Increased by 16.31%
EPS This Year
-3.59
from -2.56
EPS Next Year
-3.82
from -3.59
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 727.3M | 1.3B | 1.6B | ||
| Avg | 637.9M | 742.0M | 960.3M | ||
| Low | 584.1M | 423.8M | 627.2M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -7.7% | 102.4% | 112.1% | ||
| Avg | -19.0% | 16.3% | 29.4% | ||
| Low | -25.8% | -33.6% | -15.5% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -3.19 | -2.25 | -1.13 | ||
| Avg | -3.59 | -3.82 | -2.75 | ||
| Low | -3.84 | -5.76 | -4.15 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.